Nursing

Your Article Summary

See Latest Articles

Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture
Annals of Internal Medicine, 05/09/08

Cadarette SM et al. - Differences in fracture risk between risedronate or raloxifene and alendronate were small. Nasal calcitonin recipients may have a higher risk for nonvertebral fractures compared with alendronate recipients.

• Aim was to compare the relative effectiveness of osteoporosis treatments to reduce nonvertebral fracture risk among older adults
• 43,135 new recipients of oral bisphosphonates, nasal calcitonin, and raloxifene
• The mean age was 79 yrs, and 96% were women
• The primary outcome was nonvertebral fracture within 12 mos of treatment initiation
• Alendronate was the reference category in all analyses

• A total of 1051 nonvertebral fractures were observed within 12 mos
• No large differences in fracture risk were found between risedronate or raloxifene and alendronate
• Among those with a fracture history, raloxifene recipients experienced more nonvertebral fractures within 12 mos vs alendronate recipients
• Pts who received calcitonin experienced more nonvertebral fractures than those who received alendronate

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09

New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09

Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09

See All of Clinical Pharmacology